#### RESEARCH



# Neurological sequelae after childhood bacterial meningitis

Laura Lempinen<sup>1,2</sup> · Riste Saat<sup>1,3</sup> · Sakke Niemelä<sup>4</sup> · Anu Laulajainen-Hongisto<sup>2</sup> · Antti A. Aarnisalo<sup>2</sup> · Tea Nieminen<sup>5</sup> · Jussi Jero<sup>6</sup>

Received: 2 July 2024 / Revised: 15 September 2024 / Accepted: 18 September 2024 / Published online: 30 September 2024 © The Author(s) 2024

#### Abstract

The purpose of this study is to evaluate childhood bacterial meningitis (BM): incidence, clinical presentation, causative pathogens, diagnostics, and outcome (neurological sequelae, hearing loss, and death). A retrospective review of all children aged  $\leq 16$  years and 1 month diagnosed with BM at a tertiary children's centre in the period 2010–2020. The Glasgow Outcome Scale (GOS) was used to assess outcome, with a GOS score of 1–4 considered to be an unfavourable outcome. Logistic regression univariate analysis was used to determine predefined risk factors for death, unfavourable outcome, and long-term neurological sequelae. Seventy-four patients (44 males) with a median age of 8.0 months (range 1 day to 16 years and 1 month) and 77 BM episodes were included in the study. The average incidence rate of BM was 2.2/100,000/year, the majority (91%) being community-acquired BM. *Streptococcus pneumonia* and *Neisseria meningitidis* were the most common pathogens 12/77 (16%) each. Neurological sequelae at discharge were present in 24 (34%) patients, unfavourable outcome in 19 (25%), and hearing loss (deafness) in two (3%) survivors of BM. Seven (9%) patients died. Long-term neurological sequelae were observed in 19/60 (32%), aphasia/dysphasia being the most common in 10 (17%) BM children. No independent risk factors were identified for long-term neurological sequelae in univariate analysis.

*Conclusion:* The risk for a fatal course of BM is still remarkable. Neurological sequelae persisted in a substantial proportion of BM survivors in long-term follow-up, aphasia/dysphasia being the most common. Hearing loss (deafness) occurred in 3%. However, no specific risk factors predicting the long-term sequelae were found.

#### What is Known:

- Streptococcus pneumonia and Neisseria meningitidis were the most common pathogens causing bacterial meningitis.
- Risk for fatal course of bacterial meningitis (BM) remains remarkable despite advances in modern medicine.

#### What is New:

- In long-term follow-up, 1/3 of BM children suffered from neurological sequelae in the 2010s, aphasia and dysphasia being the most common sequelae.
- Hearing loss was diagnosed in only two (3%) children, whom of both were deaf.

Keywords Bacterial meningitis · Child · Neurological sequelae · Death · Hearing loss · Deafness

Communicated by Tobias Tenenbaum

Laura Lempinen laura.j.lempinen@hus.fi

- <sup>1</sup> HUS Medical Imaging Center, Radiology, University of Helsinki and Helsinki University Hospital, PB 340, 00029 HUS Helsinki, Finland
- <sup>2</sup> Head and Neck Surgery, Otorhinolaryngology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
- <sup>3</sup> Radiology, East Tallinn Central Hospital, Tallinn, Estonia
- <sup>4</sup> Otorhinolaryngology, University of Turku, Turku, Finland
- <sup>5</sup> Children's Hospital, Paediatrics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
- <sup>6</sup> University of Helsinki and Helsinki University Hospital, Helsinki, Finland

		•		
Δh	hre	wia	tin	nc
AN	NIC.			

AM	Acute mastoiditis
BM	Bacterial meningitis
CABM	Community-acquired bacterial meningitis
CT	Computed tomography
CSF	Cerebrospinal fluid
dB HL	Decibels Hearing Level
GBS	Group B streptococcus
GCS	Glasgow Coma Scale
GOS	Glasgow Outcome Scale
IC	Intracranial
IQR	Interquartile range
Hib	Haemophilus influenzae Type b
LO	Labyrinthitis ossification
OM	Otitis media
PCV	Pneumococcal conjugate vaccine
MRI	Magnetic resonance imaging

## Introduction

Bacterial meningitis (BM) remains life-threatening and causes significant morbidity despite improvements in modern medicine [1]. In high-income countries, the fatality rate is approximately 3–10% [2–5] and survivors of BM have a high risk for long-term disabling neurological sequelae, with estimates varying from 20 to 50% [5–7]. The most frequent neurological sequelae after BM are hearing loss, motor deficit, seizures, and cognitive deficits/mental retardation [5–8]. In several studies, the long-term disabling sequelae and hearing loss are associated with pneumococcal meningitis [5, 6, 9].

To prevent BM, many industrialized countries have introduced vaccines against the main pathogens of BM (*Hae-mophilus influenzae* type b, *Streptococcus pneumoniae*, and *Neisseria meningitidis*) into their vaccination programmes. These conjugate vaccines have had an impact on the bacterial aetiology of BM [10].

Our aim was to evaluate childhood bacterial meningitis (BM): its incidence, clinical presentation, causative pathogens, diagnostics, and outcome (neurological sequelae, hearing loss, and death).

# **Materials and methods**

#### Study design

A retrospective observational cohort study was conducted at the Department of Children and Adolescents at Helsinki University Hospital, which provides healthcare services to a population of approximately 1.7 million people. The study population included all children confirmed with BM from 1 January 2010 to 31 December 2020. Helsinki University Hospital also serves other areas in Finland as a tertiary referral centre, and seven patients came from outside the Helsinki University Hospital district. At the time of the study, the catchment population < 16 years of age in Helsinki and Uusimaa Hospital District (HUS) increased from 278,320 in 2010 to 295,525 in 2020. Over an 11-year period, the mean catchment population was 288,637, which was used to calculate the BM incidence (BM cases/100,000/year). Seven patients from outside our hospital district were excluded from the BM incidence calculation.

Patient data were obtained from an electronic database. The International Classification of Diseases (ICD) version 10 was used for data search, using the following codes: G00.0, G00.1, G00.2, G00.3, G00.8, G00.9, G01\*, G01\*A01.0, G01\*A02.2, G01\*A17.0, G01\*A32.1, G01\*A39.0, G03, G03.0, G03.1, G03.2, G03.8, G03.9, A39.0, G01\*A22.8, G05.0\*A17.8, G05.0\*A32.1, G05.0\*A39.8. A total of 178 patients' electronic medical records were assessed to obtain demographic information, clinical presentation, laboratory data, imaging, microbiological data, treatment (medical and surgical), hospital course, and outcomes.

Patients were included in the study if they had signs and symptoms suggestive of BM and met at least one of the following criteria: (1) positive cerebrospinal fluid (CSF) culture, (2) detection of bacterial DNA or antigens in CSF, (3) detection of bacteria in CSF Gram stain. (4) CSF leukocytosis >  $53 \times 10^6$ /L and CSF protein > 473 mg/L were together cut point values, if CSF culture, DNA/antigen, or CSF gram stain was negative in patients having signs and symptoms suggestive of BM.

CSF sampling failed with one newborn (age < 72 h) diagnosed with clinical meningitis: the blood culture was positive for group B streptococcus (GBS), CRP was 50 mg/L, and plasma leucocyte count was 7.7 E9/l. In addition, two cases of tuberculous meningitis with a positive B-LyTbIFN/Tb-Spot test were included in the study.

Patients with meningitis caused by borrelia or non-bacterial pathogens (virus, fungi, or parasite) were excluded.

Community-acquired BM (CABM) was defined as  $\geq 3$  days of age, BM acquired out of hospital, and no neurosurgery within the previous 30 days. Nosocomial BM was defined as symptoms occurring within 48 h after admission to the hospital, 3 days after discharge, or 30 days after neurosurgical operation [11]. BM in a newborn baby with perinatal infection from birth was also considered nosocomial.

*Haemophilus influenzae* type b vaccines have been given in the Finnish national vaccination programme at the ages of 3, 5, and 12 months since 1993. The 10-valent pneumococcal conjugate vaccine (Synflorix<sup>R</sup>, covering *S. pneumoniae*  serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F) has been given with the same schedule since the autumn of 2010. Meningococcal vaccines are not included in the Finnish national vaccination programme for children.

# **Patient data**

All magnetic resonance imaging (MRI) and computed tomography (CT) studies of the head and neck region were re-assessed by two radiologists (RS and LL) for neuroradiological findings and complications. The radiologists' reports of brain ultrasound studies were also inspected for intracranial (IC) complications. The following conditions were defined as neuroradiological complications: haemorrhage; infarction; presence of newly acquired or acerbation of hydrocephalus; venous infarction; pus in subdural, subarachnoidal space, or lateral ventricles; unknown subdural effusion/hygroma; brain herniation; brain oedema; luminal narrowing of the internal carotid artery; encephalitis; spinal epidural abscess; and labyrinthitis.

Hearing tests were done on 47/74 BM children (64%). Hearing was tested by otoacoustic emissions in 38 patients, by audiogram in seven, by behavioral observation audiometry in three, and by brainstem-evoked response audiometry in one patient. Hearing loss was defined as > 25 decibels Hearing Level (dB HL) and further subdivided into moderate (41–60 dB HL), severe (61–79 dB HL), and profound (deaf) ( $\geq$  80 dB HL). We present the hearing thresholds according to the better-ear hearing level and by each ear separately (ear-specific).

Patients were categorized according to the Glasgow Coma Scale (GCS). If GCS data collected from patient records was incomplete, the level of consciousness was estimated based on the available information. Coma was defined as need for intubation or moderately to severely altered mental status (3–8 points), altered level of consciousness as mildly altered mental status (9–12 points), and normal level of consciousness (13–15 points). The Glasgow Outcome Scale (GOS) was used to assess outcome at discharge: death (1 point), vegetative state (2 points), severe disability (3 points), moderate disability (4 points), and mild or no disability (5 points) [12]. An unfavourable outcome was defined as a GOS score of 1–4.

Long-term neurological sequelae were defined as persistent sequelae after discharge, diagnosed during hospital stay or follow-up, including hearing loss/deafness with cochlea implant, seizure disorder, dizziness, dysphasia/aphasia, isolated hypotonia/motor delay, and learning difficulties. Seizure disorder was defined as children having seizures and/or receiving prophylactic anti-epileptic drugs during follow-up, excluding patients who stopped such treatment at their first routine outpatient appointment after BM. Follow-up time ranged from 2 months to 9 years and 3 months. Twentyseven patients had less than 12 months of follow-up in specialized healthcare. After specialized healthcare follow-up, monitoring continued at child welfare clinics for preschoolers and school health services for school-aged children.

### **Statistical analyses**

Statistical analysis of the data was conducted in IBM SPSS v29. Fisher's or  $\chi^2$  exact test when appropriate was used to determine significant differences between categorical variables. The Mann–Whitney *U* test was used to analyze the correspondence of medians with the interquartile ranges (IQR) or range of continuous variables. Univariate logistic regression analysis was used to predict death, an unfavourable outcome, or long-term neurological sequelae. The results are expressed as odds ratios (OR) with a 95% confidence interval (CI<sub>95%</sub>). A two-tailed *P*-value of <0.05 was considered statistically significant.



**Fig. 1** Study flow chart. <sup>a</sup>Meningitis caused by borrelia, or non-bacterial pathogens (virus, fungi, or parasite). <sup>b</sup>BM in a newborn baby with perinatal infection from the birth was considered as nosocomial. <sup>c</sup>Intracranial malignant and benign tumour in one each. <sup>d</sup>Bacterial meningitis diagnosed < 30 days after neurosurgery

### Results

Seventy-seven BM episodes from 74 patients were included in this study (Fig. 1). The median age at diagnosis was 8.0 months (range from 1 day to 16 years and 1 month), and 44 (57%) were males. The incidence of BM in our hospital district was approximately 2.2/100,000/year. The majority (71 (92%)) were community-acquired BM (CABM). The incidence rates and aetiology of childhood bacterial meningitis per year are shown in Fig. 2. Table 1 summarizes the baseline characteristics of BM children.

# Medical history, symptoms, clinical findings, microbiology, and laboratory tests

Twenty out of 77 (26%) children had underlying chronic diseases: hydrocephalus (n=3); intracranial tumour (malignant and benign); asthma; newborn asphyxia; human immunodeficiency virus positivity; neonatal incontinentia pigmentia gravis; megalencephaly capillary malformation syndrome; sensorineural and conductive (combined) hearing impairment; Down syndrome with duodenal stenosis; lumbalic hemivertebra; neurofibromatosis type I and middle cerebral artery infarction; cheilopalatoschisis and anetoderma of Jadassohn-Pelliazari.

Nine infants aged <2 months were born preterm before 37+0 weeks of gestation: two before 27+0 weeks and the rest between 29+2 weeks and 35+5 weeks. Eight mothers tested positive for GBS. Five children had a neurosurgical operation before BM diagnosis. Four children had had BM before.

At admission, fever (> 38 °C) was present in 36/50 (72%), headache in 11/28 (39%), altered level of consciousness in

21/74 (28%), any psychomotor retardation in 14/71 (20%), petechia in 13/71 (18%), nausea/vomiting in 13/72 (18%), and seizures in 5/74 (7%). The median C-reactive protein (CRP) level at admission was 90 mg/L (IQR 45–189). During hospital treatment, the maximum median CRP in children  $\geq 2$  months old (245, IQR 153–305) was higher compared with infants < 2 months old (130, IQR 72–204; P = 0.004). Disseminated intravascular coagulation was diagnosed in six children  $\geq 2$  months old. The most common pathogen causing BM in children  $\geq 2$  months old was *N. meningitidis* (n = 12, 23%; P = 0.20), followed by *S. pneumoniae* (n = 11, 21%), and in children < 2 months old it was GBS (n = 11, 46%; P < 0.001) (Table 2). Of 21 patients with negative CSF culture, 14 (67%) had pre-diagnostic antibiotic therapy.

# Operative treatment, neuroradiological complications, and hearing results

A total of 16 operations were performed on 12 children within a median of 6.5 days (IQR 1.5–64) after diagnosis of BM. In four children, the operation was performed after discharge. The most common operation was an IC shunt operation/trepanation in seven, followed by tympanostomy in three, cochlear implantation and paranasal sinus surgery in two each, and application of ICP-monitoring (Codman) and revision of distal necrosis of fingers and toes in one each. The cochlear implantation was performed on average 2.5 months after the diagnosis. Twenty-six (34%) children were admitted to an intensive care unit. Adjunctive anticonvulsant treatment was administered to 14 (18%) patients and empiric adjunctive corticosteroid treatment to 26 (34%) patients.

Fig. 2 Incidence rates and aetiology of childhood bacterial meningitis in Southern Finland, 2010–2020. Other aetiology included *Mycobacterium tuberculosis* in 2, and grampositive cocci, *Pseudomonas aeruginosa*, *Staphylococcus epidermis*, and *Staphylococcus hominis* in one each. Unknown aetiology in 22



#### Table 1 The baseline characteristics of children diagnosed with bacterial meningitis, 2010–2020

N=1/         N=2/1         N=2/3           nN(2) so median (QR)         nN(2) so median (QR)         nN(2) so median (QR)           Demographics		All	Children aged < 2 months old	Children aged $\geq 2$ months old
Constraint         Constraint <thconstraint< th="">         Constraint         Constra</thconstraint<>		N = 77 n/N (%) or median (IOR)	N = 24 n/N (%) or median (IOR)	N = 53 n/N (%) or median (IOR)
Jean parameter of the section of th				
Age, mainsAdd (-5-3)Gas (0.5)(0.60.0) (-19.0)Sex (males)44 (47)10 (42)31 (48)Peclipospia inficcion?34 (47)10 (42)24 (45)Probrospia dimission22 (29)-22 (42) - <sup>dissour</sup> Duration of symptoms, days10 (-3)1 (-1)-122 (42) - <sup>dissour</sup> Previous antibolisc10 (25)31 (3)10 (3)Nameschomiting2075 (43)323 (13)2952 (50 (697)Preschai75 (5)-451 (8)Stetares175 (15)1/23 (4)052 (19)Cona275 (43)1/23 (3)052 (19)Cona175 (5)1/23 (4)052 (19)Cona175 (15)1/23 (4)1128 (39)Chaisa and laboratory findings on admission1/73 (18)222 (9)Heachia177 (18)222 (9)1149 (22)Massachomiting1673 (22)-1448 (3)Massachomiting1673 (22)2/14 (80)243 (6)(7)Patchia21/70 (9)1/21 (48)243 (6)(7)Princhia21/71 (28)2/14 (80)4/13 (18)Seizures574 (7)1/401/14 (19)Seizures17/4 (28)6/25 (13)1/26 (18)Patchia10 (5) (5) (5)1/21 (18)1/21 (19)Any neurological sequeds <sup>4</sup> 21/4 (28)1/31 (18)Any neurological sequeds <sup>4</sup> 21/4 (28)1/31 (18)Coma10 (14 (28)1/31 (18)1/31 (18)Coma10 (14 (28)1/31 (19)1/31 (18) <td>Demographics</td> <td>80(1255)</td> <td>0.8(0.2, 1.2)</td> <td>10.0 (6.0, 110.0) \$0,0001</td>	Demographics	80(1255)	0.8(0.2, 1.2)	10.0 (6.0, 110.0) \$0,0001
Jack much)Jack much)Jack much)Jack much)Jack much)Peediapsing intertion"34 (44)1042)24 (45)Piner beginves infection symptoms2 (29)2 (42) «4000Duration of symptoms, days1 (1-3)1 (1-1)2 (1-5) «4000Duration of symptoms, days1 (1-3)3 (13)105)1050Previous antibiotic10 (25)3 (13)2052 (56) <sup>6000</sup> Preschin474 (5)451 (8)Seizures475 (5)123 (4)1052 (19)252 (9)Coma0 (27) (5)123 (4)0052 (19)10052 (19)Coma0 (27) (5)123 (4)11/92 (2)1049 (2)Mascar/omning1073 (2)-1049 (3) <sup>4000</sup> Mascar/omning1073 (2)-1049 (2)Mascar/omning1073 (2)21 (40)1049 (2)Mascar/omning1073 (2)21 (40)1049 (2)Nascar/omning1073 (2)1221 (57)1046 (3) <sup>4000</sup> Peechia1073 (2)1221 (57)1046 (3) <sup>4000</sup> Privable (age 59 months2057 (59)1221 (57)1046 (3) <sup>4000</sup> Sciaures506 (72)1214 (80)247 (50)Dyapace (ar-68)1068 (15)421 (19)450 (8)Parental Evel of consciouses2174 (28)3 (13)181 (81-23) <sup>4000</sup> Coma2174 (28)3 (13)1850 (5) <sup>4000</sup> Coma2174 (28)6 (25)353 (5) (25) <sup>4000</sup> Coma2174 (28)3 (13)181 (81-23) <sup>40</sup>	Age, months	8,0 (1.3-33)	0.8(0.3-1.3)	19.0 (6.0–119.0)
Precisionsing miccion*         js (4)         (0.42)         (2.43)           Dipersions indiussion         22         (2) " <sup>0.0001</sup> Duration of symptoms, days         12.3)         1.4.1-1         22.1.5) " <sup>0.0001</sup> Duration of symptoms, days         1925         313.3         16.30           Nausea/vomiting         3275 (3)         323.1(3.1)         451.8           Seizures         475 (5)         -         451.8           Seizures         475 (5)         -         451.8           Coma         275 (3)         -         22.4 (4)           Coma         275 (3)         -         22.4 (4)           Menings on admission         -         -         448.3 (3)           Vice databach (age 2-16 months)         1072 (18)         22.2 (9)         1149 (22)           Meningsal irritation         1073 (18)         22.3 (9)         1148 (3)           Freechia         1377 (18)         22.3 (9)         144 (42)           Freechia         1073 (18)         22.1 (57)         1046 (53)           Spymose (n=68)         1048 (51 (5)         241 (19)         447 (5)           Spymose (n=68)         1048 (51 (2)         211 (19)         447 (5)           Spymose (n=	Sex (males)	44 (57)	13 (34)	31 (38)
Prior basiling infection symptoms         22 (2)         -         24 (2)         4000000000000000000000000000000000000	Price beneficial administration	34 (44)	10 (42)	24 (45)
Tapper Respiratory miceus sympons         22 (29)         -         22 (25)           Duration of sympons, days         10 (-3)         1 (-1)         21 (-5)         30000           Nansea/romiting         302 (3)         323 (13)         2952 (6) 0.000           Nansea/romiting         474 (5)         -         451 (8)           Seizares         475 (5)         -         451 (8)           Altered level of consciousnes         175 (15)         123 (4)         1052 (19)           Coma         275 (3)         -         252 (4)           Eleadabe (age 2-16 nom4s)         1128 (39)         -         1128 (39)           Nansea/romiting         1377 (18)         222 (9)         1149 (22)           Meningeal initiation         1371 (18)         223 (9)         1148 (3)           Petechiae         1371 (18)         223 (9)         1148 (2)           Petechiae         1371 (18)         213 (19)         1066 (3)           Seizares         373 °C         3650 (7)         121 (48)         3000           Dyspone (r=68)         1066 (15)         421 (19)         450 (8)           Seizares         574 (7)         14 (4)         450 (8)           Seizares         574 (7)         14 (3) <td>United and the second s</td> <td>22 (20)</td> <td></td> <td>22 (42) \$0,0001</td>	United and the second s	22 (20)		22 (42) \$0,0001
Juntano (symptoms, days)         1 (1-)         1 (1-)         2 (1-3)           Derivision attivitionic         19 (25)         3 (13)         16 (60)           Names/vomiting         275 (3)         322 (13)         29/2 (56) <sup>6007</sup> Petechin         474 (5)         -         451 (8)           Sciarzes         475 (5)         1/23 (4)         10/52 (19)           Coma         275 (3)         1/23 (4)         10/52 (19)           Coma         275 (3)         -         11/28 (9)           Sciarzes         11/28 (39)         -         11/28 (9)           Manses/vomiting         13/72 (18)         222 (9)         11/28 (9)           Meningeal initation         16/73 (22)         -         1649 (3) <sup>nond</sup> Meningeal initation         16/73 (22)         -         10/16 (63)           Peterbia         13/71 (18)         221 (9)         10/16 (63)           Sciarzes         10/66 (14)         -         9/17 (19)           Sciarzes         574 (7)         12/14 (80)         6/16 (1)           Sciarzes         574 (7)         16/14         -           Triatiol (qiece, alteral level of consciousnes, and meningral initation) (n=60         11/4 (28)         6/15 (1)	Direction of comparison down	22 (29)	-	22(42)
Trebuos anunous19 (2)3 (1)10 (0)Prenchia24/75 (3)3 (23 (13)29/52 (66) (ame)Petechia47.6 (5)-451 (8)Seiznes47.5 (5)1/23 (4)052 (4)Coma27.5 (3)-252 (4)Coma11/75 (15)1/23 (4)052 (19)Coma11/28 (39)-11/28 (39)Iedache (age 2 16 months)11/28 (7)222 (9)11/49 (22)Nausea/vomiting1673 (22)-14/49 (23) (ame)Petechia16/71 (22)223 (9)11/48 (23)Petechia16/71 (3)221 (5)01/16 (63)Petechia16/71 (3)221 (5)01/16 (63)Petechia16/71 (19)12/14 (86)24/66 (7)Ferer 37 J9 "C3650 (7)12/14 (86)24/36 (67)Petechia10/16 (5)12/14 (86)44/60 (8)Seizuras01/66 (14)Triad (fever, aftered level of consciousness, an ueringical irritation) (n =66)16/61 (4)-Coma17/4 (28)6 (15)45/10 (3) (3)Coma17/4 (28)3 (13)15/80 (3) (3)Coma17/4 (28)3 (13)15/80 (3) (3)Coma17/4 (28)3 (13)15/80 (3) (3)Coma15/9 (6)12/10 (4)12/10 (4)Coma15/9 (6) (16, 12)90 (59-30, 20)130 (125-300)Coma15/9 (6) (16, 12)16/10 (16, 12)12/10 (10, 12) (16, 12)Coma15/9 (16, 12)16/10 (16, 12)12/10 (10,	Duration of symptoms, days	1(1-3)	1(1-1)	2(1-5)
Names         Subs         Subs         Subs           Petechia         4/74 (5)         -         4/51 (8)           Seizures         4/75 (5)         -         4/51 (8)           Altered level of consciousness         11/75 (15)         1/23 (4)         0/52 (19)           Corna         2/75 (3)         -         11/28 (39)           Corna         2/75 (3)         -         11/28 (39)           Mussel/omiting         11/28 (39)         -         11/28 (39)           Mussel/omiting         13/72 (18)         2/22 (9)         11/48 (23)           Mussel/omiting         16/57 (22)         -         11/48 (23)           Petechia         3/57 (18)         2/21 (57)         10/16 (63)           Dyspance (n=68)         0/66 (1)         1/21 (19)         6/76 (13)           Scitzures         5/74 (7)         1/4 (28)         1/50 (30)           Corna         7/74 (9)         3 (13)         4/50 (8)           Corna         1/74 (13)         5/50 (30)         1/10 (19)           Corna         7/74 (9)         3 (13)         4/50 (8)           Corna         1/74 (13)         0/13 (13)         4/50 (8)           Corna         1/74 (9)         0/22 (	Previous antibiotic	19(25)	3 (13)	10(50)
retenta         4/75 (5)         -         4/51 (8)           Sciaures         4/75 (5)         -         4/51 (8)           Ahreed level of consciousness         1/75 (15)         1/23 (4)         1052 (19)           Coma         207 (3)         -         -         22 (4)           Cincial and laboratory findings on admission         11/28 (39)         -         11/28 (39)           Nausea/vomiting         11/28 (37)         2/20 (9)         11/48 (23)           Meningeal irritation         16/73 (2)         -         16/49 (33) <sup>600/</sup> Petechiae         13/71 (18)         223 (9)         11/48 (23)           Diritable (age ≥ 10 months)         10/73 (18)         12/21 (57)         10/64 (63)           Diritable (age ≥ 9 months         2/2/7 (7)         12/21 (7)         10/16 (63)           Dispance (n = 68)         2/47 (7)         14 (4)         450 (8)           Scizures         5/74 (7)         14 (4)         450 (8)           Triad (ser, altered level of consciousness, and         9/66 (14)         -         -           Any neurological sequelae <sup>8</sup> 2/174 (28)         6 (25)         13/9 (8)           Coma         7/76 (9)         3 (13)         151 (81-22.3) <sup>(0/M/I</sup> <t< td=""><td>Nausea/vomiting</td><td>32/75 (43)</td><td>3/23 (13)</td><td>29/52 (56)</td></t<>	Nausea/vomiting	32/75 (43)	3/23 (13)	29/52 (56)
Serures         475 (5)         -         471 (8)           Alvered level of consciousness         11/75 (5)         1/23 (4)         1052 (19)           Coma         2/75 (3)         -         252 (4)           Indicator for consciousness         11/28 (30)         -         11/28 (39)           Nausea/vonting         11/28 (7)         222 (9)         11/49 (22)           Meningeal infration         1673 (22)         -         1649 (23)           Petechia         13/71 (18)         222 (9)         11/48 (23)           Petechia         13/71 (18)         221 (57)         11/48 (23)           Dyspace (n=68)         06/60 (72)         12/14 (86)         24/76 (67)           Scizures         574 (7)         12/14 (86)         4/71 (19)         6/80 (7)           Scizures         574 (7)         14/28)         6 (25)         5/50 (00)           Coma         7/74 (9)         3 (13)         4/70 (8)         8/50 (3)           Altered level of consciousnes         21/74 (28)         3 (13)         15/8 (6)           Coma         7/74 (9)         0/23 (0)         3/8 (6)         16/8 (1)           Coma         120 (5.9-19.6)         6 (35.5-99.25)         97 (3-199)         16/8 (3)	Petechia	4/74 (5)	-	4/51 (8)
Altered level of consciousness         11/5 (15)         1/2 (3)         10/2 (3)           Coma         2/5 (3)         -         2/5 (4)           Elandach (age ≥ 16 nonths)         11/28 (3)         -         11/28 (3)           Nausca/romiting         13/7 (18)         2/23 (9)         11/49 (2)           Meningeal irritation         1673 (2)         -         16/49 (3) <sup>0.001</sup> Petechiae         37/1 (18)         2/23 (9)         11/48 (2)           Tritable (age ≤ 9 nonths)         205 (5)         12/21 (57)         10/16 (6)           Dyspone (n = 68)         10/68 (15)         4/21 (19)         6/47 (13)           Seiznes         10/68 (15)         4/21 (19)         6/30           Triad (feve, altered level of consciousness, and meningeal irritation (n = 66)         -         9/47 (19)           Cona         7/74 (9)         3 (13)         4/50 (8)           Canain areve paby <sup>6</sup> 21/74 (28)         3 (13)         4/50 (8)           Canain areve paby <sup>6</sup> 17/4 (28)         6 (25)         5/50 (3)           Canain areve paby <sup>6</sup> 17/4 (28)         6 (25)         5/50 (3)           Canain areve paby <sup>6</sup> 12/0 (5)         16 (10 (5)         9/20 (20)           Blood culture posit	Seizures	4/75 (5)	-	4/51 (8)
Coma         Cols 20	Altered level of consciousness	11//5 (15)	1/23 (4)	10/52 (19)
Christand laboratory indrigs on admission         IL28 (39)         IL28 (39)         IL28 (39)           Headach (ag ≥ 16 months)         1072 (18)         2/22 (9)         11/49 (22)           Meningeal irritation         16/37 (22)         -         16/49 (33) <sup>000/</sup> Petechiae         3/71 (18)         2/23 (9)         11/48 (23)           Petechiae         3/71 (18)         2/21 (80)         11/48 (23)           Irritable (ag ≤ 9 months         2/237 (59)         12/21 (87)         0/16 (63)           Dyspoce (n = 68)         0/68 (15)         4/21 (19)         6/47 (13)           Scizures         5/74 (7)         14 (40)         4/50 (8)           Triad (fever, altered level of consciousness, and mentingeal irritation) (n = 66)         5/74 (7)         14 (40)         15/50 (30)           Coma         7/74 (9)         6 (25)         15/50 (30)         15/50 (30)           Coma         7/74 (8)         3 (13)         18/50 (36) <sup>0/26</sup> Crania nerve palsy <sup>6</sup> 2/174 (28)         3 (13)         15.1 (8.1-22.3) <sup>0/03</sup> B-Leukocytes (x10 <sup>9</sup> / <sub>0</sub> ) (n = 75)         2/0 (4-18)         2/2 (0)         3/48 (6)           Crania nerve palsy <sup>6</sup> 3/70 (4)         2/2 (0)         3/48 (6)           Cone (mg/L) (n = 66) <td></td> <td>2//5 (3)</td> <td>-</td> <td>2/52 (4)</td>		2//5 (3)	-	2/52 (4)
Headache (age ≥ 16 months)         1/128 (39)         -         11/28 (39)           Nausea/vomiting         1372 (18)         222 (9)         11/49 (22)           Meningeal irritation         1673 (22)         -         1649 (33) <sup>0.007</sup> Petechiae         1371 (18)         222 (9)         11/48 (23)           Fever> 37.9 °C         36/50 (72)         12/14 (86)         24/36 (67)           Dyspnoce (n = 68)         2237 (59)         12/14 (7)         10/16 (63)           Seizures         57/4 (7)         1 (4)         4/50 (8)           Triad (ege 5 of constissens, and meningeal irritation) (n = 66)         15/50 (30)         25/60 (8)           Any neurological sequelae <sup>b</sup> 21/74 (28)         3 (13)         18/50 (8)           Any neurological sequelae <sup>b</sup> 21/74 (28)         3 (13)         18/50 (36) <sup>0.026</sup> Coman         7/74 (9)         3(13)         18/50 (36) <sup>0.026</sup> Creacitic protic (mg/L) dayl (n = 75)         9(45 - 189)         52 (33.5 - 99.25)         97 (53-199)           Blood culture positive (n = 69)         47 (61)         18 (75 - 300)         103 (125-300)           CSF leucocyte coun (L 10 <sup>f/L</sup> ) dayl (n = 70)         13/9 (21-2923)         1920 (59-3028)         1130 (125-300)           CSF eptotein (mg/L)	Clinical and laboratory findings on admission			
Name         13/12 (18)         222 (9)         1149 (22)           Meningeal irritation         16/3 (22)         -         1649 (33) <sup>6007</sup> Petechia         13/71 (18)         223 (9)         1148 (23)           Fver>> 37.9 °C         36/50 (72)         12/14 (86)         24/36 (67)           Irritable (age 59 months         2037 (59)         12/21 (57)         10/16 (63)           Dyspnoce (n=68)         10/68 (15)         4/21 (19)         6/77 (13)           Scizures         574 (7)         1 (4)         4/50 (8)           Altered level of consciousness, and meningeal irritation (n=66)         9/66 (14)         -         9/47 (19) <sup>60/05</sup> Coma         7/74 (9)         3 (13)         4/50 (8)           Caraial nerve palsy <sup>6</sup> 21/74 (28)         6 (25)         15/50 (3)           Cranal nerve palsy <sup>6</sup> 21/74 (28)         3 (13)         4/50 (8)           Cranal nerve palsy <sup>6</sup> 21/74 (28)         6 (25)         3/6 (8)           Cranal nerve palsy <sup>6</sup> 21/74 (28)         8 (25)         3/6 (8)           Cranal nerve palsy <sup>6</sup> 3/70 (4)         0/22 (0)         3/48 (6)           B-Leukoyets (x10 <sup>0</sup> / <sub>1</sub> ) day1 (n=75)         90 (45-189)         82.5 (33.5-99.25)         9 (3.5 (4) <td>Headache (age <math>\geq 16</math> months)</td> <td>11/28 (39)</td> <td>-</td> <td>11/28 (39)</td>	Headache (age $\geq 16$ months)	11/28 (39)	-	11/28 (39)
Memogal irritation         16/73 (22)         -         1649 (33)           Petechiae         13/71 (18)         2/23 (9)         11/48 (23)           Petechiae         3/71 (18)         2/23 (9)         1/14 (86)         2/436 (67)           Irritable (age $\leq 9$ months         2/37 (59)         12/21 (57)         10/16 (63)           Dysponea ( $n = 68$ )         10/68 (15)         4/21 (19)         6/47 (13)           Scizures         5/74 (7)         1 (4)         4/50 (8)           Triad (fiver, altered level of consciousness, and meningeal irritation) ( $n = 66$ )         5/74 (7)         1 (4)         4/50 (8)           Coma         7/74 (9)         3 (13)         4/50 (8)           Coma         7/74 (9)         3 (13)         18/50 (36) $^{0.026}$ Cranial nerve palsy <sup>6</sup> 21/74 (28)         3 (13)         18/50 (36) $^{0.026}$ Cranial nerve palsy <sup>6</sup> 3/70 (4)         0/22 (0)         3/48 (6)           B-Leukocytes (x10 <sup>0</sup> ), dayl ( $n = 75$ )         12.0 (5.9-19.6)         6.7 (3.5-13.3)         15.1 (8.1-22.3) $^{0.027}$ Cracative protein (mg/L) dayl ( $n = 75$ )         3/60 (4)         16.7 (3         29/45 (64)           CSF protein (mg/L) dayl ( $n = 75$ )         15.0 (8.1-20.5)         13.0 (12-5-3200)	Nausea/vomiting	13/72 (18)	2722 (9)	11/49 (22)
Precentale         13/1 (18)         223 (9)         11/48 (2.5)           Fever> 37.9 °C         36/50 (72)         12/14 (86)         24/36 (67)           Initiable (age ≤9 nonths         22/37 (59)         12/14 (86)         24/36 (67)           Dyspnoca (n=68)         10/68 (15)         4/21 (19)         6/47 (13)           Seizures         57/4 (7)         1 (4)         4/50 (8)           Triad (fever, altered level of consciousness, and meningeal initiation (n=66)         9/47 (19) <sup>0.035</sup> 9/47 (19) <sup>0.035</sup> Altered level of consciousness         21/74 (28)         6 (25)         15/50 (30)           Coma         7/74 (9)         3 (13)         4/50 (8)           Any neurological sequelae <sup>b</sup> 21/74 (28)         6 (25)         15/50 (30)           Cranai nerve palsy <sup>C</sup> 3/70 (4)         022 (00         3/48 (6)           B-Leukocytes (x 10 <sup>9</sup> ), day1 (n=75)         12 (0 (59–19.6)         6.7 (3.5–13.3)         151 (8.1–22.3) <sup>0.002</sup> C-reative protein (mg/L) day1 (n=75)         90 (45–189)         82.5 (3.3–599.2)         97 (33–109)           Blood culture positive (n=69)         47 (61)         18 (75         29/45 (64)           CSF erythrocytes (x 10 <sup>9</sup> /L) (n=68)         16 (30–697)         418 (54–310)         180 (17–60)         130 (125	Meningeal irritation	16/73 (22)	-	16/49 (33) 0.001
Fevery 37.9 °C         36/30 (72)         12/14 (86)         24/36 (67)           Irritable (age 59 months         22/37 (59)         12/21 (57)         10/16 (63)           Dyspnoce (n=68)         10/68 (15)         4/21 (19)         6/47 (13)           Scizures         574 (7)         1 (4)         4/50 (8)           Triad (fever, altered level of consciousness, and meningeal irritation) (n=66)         9/66 (14)         -         9/47 (19) <sup>0.035</sup> Altered level of consciousness         21/74 (28)         6 (25)         15/50 (30)           Coma         774 (9)         3 (13)         4/50 (8)           Any neurological sequelae <sup>b</sup> 21/74 (28)         3 (13)         15/30 (30) <sup>0.006</sup> Cranial nerve palsy <sup>C</sup> 370 (4)         022 (0)         3/48 (6)           B-Leukocytes (x10 <sup>0</sup> ), day1 (n=75)         90 (45-189)         82.5 (33.5-99.25)         97 (53-19)           Blood culture positive (n=69)         47 (61)         18 (75)         29/45 (64)           CSF leucocyte count (x10 <sup>6</sup> /1, day1 (n=75)         90 (45-189)         1300 (25-2302)         1300 (125-3200)           CSF protein (mg/L, 0a=66)         1706 (98-2753)         1845 (12-23)         29/10-0-11         29/10-0-11           CSF glucose (mon/L/, (n=63)         2 (3 (0-2-35)         180 (17	Petechiae	13//1 (18)	2/23 (9)	11/48 (23)
Irritable (age $\leq$ 9 months22/37 ( $\leq$ 99)12/21 ( $\leq$ 17)10/16 ( $\in$ 6.5)Dyspnoea ( $n = 68$ )10/68 (15)4/21 (19)6/47 (13)Seizures57/4 (7)1 (4)4/50 (8)Triad (fever, altered level of consciousness, and meningeal irritation) ( $n = 66$ )9/47 (19) ( $^{0.055}$ Altered level of consciousness21/74 (28)6 (25)15/50 (30)Coma77/4 (9)3 (13)4/50 (8)Any neurological sequelae <sup>b</sup> 21/74 (28)3 (13)18/50 (36) ( $^{0.056}$ Comia77/4 (9)3 (13)18/50 (36) ( $^{0.056}$ Any neurological sequelae <sup>b</sup> 21/74 (28)6 (7 (3.5-13.3)15.1 (8.1-22.3) ( $^{0.003}$ Cranit nerve palsy3/70 (4)0/22 (0)3/48 (6)B-Leukocytes (x 10 <sup>6</sup> ), day1 ( $n = 75$ )120 (5.9-19.6)6.7 (3.5-13.3)15.1 (8.1-22.3) ( $^{0.003}$ Cranit (mg/L) day1 ( $n = 75$ )90 (45-189)120 (592-302.8)1130 (125-3200)SGF protein (mg/L) day1 ( $n = 70$ )1359 (213-292.3)120 (592-302.8)1130 (125-3200)CSF protein (mg/L) ( $n = 66$ )1706 (982-275.3)1846 (122-24.35)1291(702-3140)CSF protein (mg/L) ( $n = 65$ )2.3 ( $0.9-3.6$ )1845 (1.2-2.5)2.9 (1.0-4.1)CSF protein (mg/L) ( $n = 65$ )2.3 ( $0.9-3.6$ )1845 (1.2-2.5)2.9 (1.0-4.1)CSF glucose (nmol/L) ( $n = 63$ )2.3 ( $0.9-3.6$ 1845 (1.2-2.5)2.9 (1.0-4.1)CSF glucose (nmol/L) ( $n = 63$ )2.3 ( $0.9-3.6$ 182 (37)30/47 (64)Duringif ( $n = 63$ )2.3 ( $0.9-3.6$ 182 ( $3.6$ 3	Fever > 37.9 °C	36/50 (72)	12/14 (86)	24/36 (67)
Dyspoec (n = 68)         1068 (15)         4/21 (19)         6/47 (13)           Seizures         5/74 (7)         1 (4)         4/50 (8)           Triad (fever, altered level of consciousness, and meningeal irritation) (n = 66)         9/66 (14)         -           Altered level of consciousness         21/74 (28)         6 (25)         15/50 (30)           Coma         7/74 (9)         3 (13)         4/50 (8)           Any neurological sequelae <sup>b</sup> 21/74 (28)         3 (13)         4/50 (8)           Grania Inerve palsy <sup>c</sup> 3/70 (4)         0/22 (0)         3/48 (6)           B-Leukocytes (x10 <sup>9</sup> ), day1 (n=75)         12.0 (5.9–19.6)         6.7 (3.5–13.3)         15.1 (8.1–22.3) <sup>0.003</sup> Creactive protein (mg/L) day1 (n=75)         90 (45–189)         82.5 (33.5–99.25)         97 (53–199)           Blod culture positive (n=69)         47 (61)         18 (75)         29/45 (64)           CSF leucocyte count (x10 <sup>6</sup> /L) day1 (n=70)         1359 (213–2923)         1291(702–3140)           CSF protein (mg/L) (n=66)         161 (30–697)         148 (54 -3310)         180 (17–600) <sup>0.033</sup> CSF poluco (mol/L) (n=63)         2.3 (0.9–3.6)         1852 (1.2–2.5)         2.9 (1.0–4.1)           CSF cluture detection of pathogen <sup>d</sup> 5776 (72)         18 (53 (3.7)         40 (	Irritable (age $\leq 9$ months	22/37 (59)	12/21 (57)	10/16 (63)
Seizures         5/74 (7)         1 (4)         4/50 (8)           Triad (fiver, altered level of consciousness, and meningeal irritation) (n = 66)         9/67 (19) <sup>0.035</sup> Altered level of consciousness         21/74 (28)         6 (25)         15/50 (30)           Coma         7/74 (9)         3 (13)         4/50 (8)           Any neurological sequelae <sup>b</sup> 21/74 (28)         3 (13)         18/50 (36) <sup>0.036</sup> Crania nerve palsy <sup>c</sup> 3/70 (4)         0/22 (0)         3/48 (6)           Grania nerve palsy <sup>c</sup> 3/70 (4)         0/22 (0)         3/48 (6)           C-reactive protein (mg/L) day1 (n=75)         90 (45–189)         82.5 (33.5–99.25)         97 (53–199)           Blood culture positive (n=69)         47 (61)         18 (75)         29/45 (64)           CSF leucocyte count (x10 <sup>6</sup> /L) (a) (a) (n=70)         1359 (213–2923)         1920 (592–3028)         1130 (125–3200)           CSF protein (mg/L) (n=66)         161 (30–697)         418 (54–3310)         180 (17–660) <sup>0.033</sup> CSF glucose (mmol/L) (n=63)         2,3 (0,9–3.6)         1.85 (1.2–2.5)         2.9 (1.0–4.1)           CSF glucose (mmol/L) (n=63)         2,3 (0,9–3.6)         1.85 (1.2–2.5)         2.9 (1.0–4.1)           Durot culture positive         130 (09)         1.82 (3.78) <t< td=""><td>Dyspnoea <math>(n=68)</math></td><td>10/68 (15)</td><td>4/21 (19)</td><td>6/47 (13)</td></t<>	Dyspnoea $(n=68)$	10/68 (15)	4/21 (19)	6/47 (13)
Triad (fever, altered level of consciousness, and meningeal irritation) (n = 66)         9/66 (14)         -         9/47 (19) 0000           Altered level of consciousness         21/74 (28)         6 (25)         15/50 (30)           Coma         7/74 (9)         3 (13)         4/50 (8)           Any neurological sequelae <sup>b</sup> 21/74 (28)         3 (13)         18/50 (36) 00.36           Cranial nerve palsy <sup>c</sup> 370 (4)         0/22 (0)         3/48 (6)           B-Leukocytes (x 10 <sup>9</sup> ), dayl (n=75)         12.0 (5.9-19.6)         6.7 (3.5-13.3)         15.1 (8.1-22.3) 0.003           C-reactive protein (mg/L) dayl (n=75)         90 (45-189)         82.5 (33.5-99.25)         97 (53-199)           Blood culture positive (n=69)         47 (61)         18 (75)         29/45 (64)           CSF leucocyte count (x 10 <sup>6</sup> /L) dayl (n=70)         1359 (213-2923)         1920 (592-3028)         1130 (125-3200)           CSF protein (mg/L) (n=66)         1706 (985-2753)         1846.5 (1226-2435)         1291(702-3140)           CSF glucose (mon/L) (n=63)         2.3 (0.9-3.6)         1.8 (12-2.5)         2.9 (1.0-4.1)           CSF culture detection of pathogen <sup>d</sup> 5/76 (72)         16 (33         30/47 (64)           During hospital stay         -         -         10 (19)           Coma <td< td=""><td>Seizures</td><td>5/74 (7)</td><td>1 (4)</td><td>4/50 (8)</td></td<>	Seizures	5/74 (7)	1 (4)	4/50 (8)
Altered level of consciousness         21/74 (28)         6 (25)         15/50 (30)           Coma         77/4 (9)         3 (13)         4/50 (8)           Any neurological sequelae <sup>b</sup> 21/74 (28)         3 (13)         18/50 (36) <sup>0.026</sup> Cranial nerve palsy <sup>6</sup> 3/70 (4)         0/22 (0)         3/48 (6)           B-Leukocytes (x10 <sup>0</sup> ), dayl (n=75)         12.0 (5.9–19.6)         67.35–13.3)         15.1 (8.1–22.3) <sup>0.003</sup> C-reactive protein (mg/L) dayl (n=75)         90 (45–189)         82.5 (33.5–99.25)         97 (53–199)           Blod culture positive (n=69)         47 (61)         18 (75)         29/45 (64)           CSF protein (mg/L) (n=66)         1706 (985–2753)         1846.5 (1226–2435)         1291(702–3140)           CSF protein (mg/L) (n=66)         161 (30–697)         418 (54–3310)         180 (17–660) <sup>0.033</sup> CSF glucose (mmol/L) (n=63)         2.3 (0.9–3.6)         1.85 (1.2–2.5)         2.9 (1.0–4.1)           CSF culture detection of pathogen <sup>d</sup> 55/76 (72)         15 (63)         40 (75)           Blod culture positive         48/70 (69)         18/23 (78)         30/47 (64)           During         13 (17         3 (13)         10 (19)           Seizures         18 (23)         10 (42)         8 (15) <sup>0.025</sup>	Triad (fever, altered level of consciousness, and meningeal irritation) $(n=66)$	9/66 (14)	-	9/47 (19) 0.055
Coma         7/74 (9)         3 (13)         4/50 (8)           Any neurological sequelae <sup>b</sup> 21/74 (28)         3 (13)         18/50 (36) <sup>0.036</sup> Any neurological sequelae <sup>b</sup> 3/70 (4)         0/22 (0)         3/48 (6)           B-Leukocytes (×10 <sup>9</sup> ), day1 (n=75)         12.0 (5.9–19.6)         6.7 (3.5–13.3)         15.1 (8.1–22.3) <sup>0.003</sup> C-reactive protein (mg/L) day1 (n=75)         90 (45–189)         82.5 (33.5–99.25)         97 (53–199)           Blood culture positive (n=69)         47 (61)         18 (75)         29/45 (64)           CSF leucocyte count (×10 <sup>6</sup> /L) day1 (n=70)         1359 (213–2923)         1920 (592–3028)         1301 (125–3200)           CSF protein (mg/L) (n=66)         1706 (985–2753)         1846.5 (1226–2435)         1291(702–3140)           CSF glucose (mmol/L) (n=63)         2.3 (0.9–3.6)         185 (1.2–2.5)         2.9 (1.0–4.1)           CSF culture detection of pathogen <sup>d</sup> 557/6 (72)         15 (63)         30/47 (64)           During hospital stay         13 (17)         3 (13)         10 (19)           Seizures         18 (23)         10 (42)         32 (60)           Any neurological sequelae <sup>b</sup> 18 (23)         10 (42)         32 (60)           Intensive care unit admission         26 (34)         6 (25) </td <td>Altered level of consciousness</td> <td>21/74 (28)</td> <td>6 (25)</td> <td>15/50 (30)</td>	Altered level of consciousness	21/74 (28)	6 (25)	15/50 (30)
Any neurological sequelæ <sup>b</sup> 21/74 (28)         3 (13)         18/50 (36) <sup>0.036</sup> Cranial nerve palsy <sup>c</sup> 3/70 (4)         0/22 (0)         3/48 (6)           B-Leukocytes (× 10 <sup>9</sup> ), day1 (n=75)         12.0 (5.9–19.6)         6.7 (3.5–13.3)         15.1 (8.1–22.3) <sup>0.003</sup> C-reactive protein (mg/L) day1 (n=75)         90 (45–189)         82.5 (33.5–99.25)         97 (53–199)           Blod culture positive (n=69)         47 (61)         18 (75)         29/45 (64)           CSF leucocyte count (x 10 <sup>6</sup> /L) day1 (n=70)         1359 (213–2923)         1920 (592–3028)         1130 (125–3200)           CSF protein (mg/L) (n=66)         1706 (985–2753)         1846.5 (1226–2435)         1291(702–3140)           CSF erythrocytes (x 10 <sup>6</sup> /L) (n=68)         161 (30–697)         418 (54–3310)         180 (17–660) <sup>0.033</sup> CSF erythrocytes (x 10 <sup>6</sup> /L) (n=63)         2.3 (0.9–3.6)         1.85 (1.2–2.5)         2.9 (1.0–4.1)           CSF culture detection of pathogend         57/6 (72)         15 (63)         40 (75)           Blod culture positive         48/70 (69)         31(3)         10 (19)           CSF culture detection of pathogend         13 (17)         3 (13)         10 (19)           Seizures         18 (23)         10 (42)         8 (15) <sup>0.0025</sup> Any neurologi	Coma	7/74 (9)	3 (13)	4/50 (8)
Cranial nerve palsy <sup>c</sup> 3/70 (4)         0/22 (0)         3/48 (6)           B-Leukocytes (×10 <sup>9</sup> ), day1 (n=75)         12.0 (5.9–19.6)         6.7 (3.5–13.3)         15.1 (8.1–22.3) <sup>0.003</sup> C-reactive protein (mg/L) day1 (n=75)         90 (45–189)         82.5 (33.5–99.25)         97 (53–199)           Blood culture positive (n=69)         47 (61)         18 (75)         29/45 (64)           CSF leucocyte count (x10 <sup>6</sup> /L) day1 (n=70)         1359 (213–2923)         1920 (592–3028)         1130 (125–3200)           CSF protein (mg/L) (n=66)         1706 (985–2753)         1846.5 (1226–2435)         1291 (702–3140)           CSF protex (x10 <sup>6</sup> /L) (n=68)         161 (30–697)         418 (54–3310)         180 (17–660) <sup>.0033</sup> CSF glucose (mmol/L) (n=63)         2.3 (0.9–3.6)         1.85 (1.2–2.5)         2.9 (1.0–4.1)           CSF culture detection of pathogend         5/76 (72)         15 (63)         40 (75)           Blood culture positive         48/70 (69)         8/10 (3)         10 (19)           coma         13 (17)         3 (13)         10 (19)           Seizures         18 (23)         10 (42)         8 (15) <sup>.0025</sup> Any neurological sequelae <sup>b</sup> 46 (60)         14 (58)         20 (038)           Adjunctive anticonvulsant treatment         14 (18)	Any neurological sequelae <sup>b</sup>	21/74 (28)	3 (13)	18/50 (36) <sup>0.036</sup>
B-Leukocytes (× 10 <sup>9</sup> ), day1 (n=75)         12.0 (5.9–19.6)         6.7 (3.5–13.3)         15.1 (8.1–22.3) <sup>0.003</sup> C-reactive protein (mg/L) day1 (n=75)         90 (45–189)         82.5 (33.5–99.25)         97 (53–199)           Blood culture positive (n=69)         47 (61)         18 (75)         29/45 (64)           CSF leucocyte count (× 10 <sup>6</sup> /L) day1 (n=70)         1359 (213–2923)         1920 (592–3028)         1130 (125–3200)           CSF protein (mg/L) (n=66)         1706 (985–2753)         1846.5 (1226–2435)         1291/702–3140)           CSF erythrocytes (× 10 <sup>6</sup> /L) (n=68)         161 (30–697)         418 (54–3310)         180 (17–660) <sup>0.033</sup> CSF glucose (mmol/L) (n=63)         2.3 (0.9–3.6)         1.85 (1.2–2.5)         2.9 (1.0–4.1)           CSF culture detection of pathogen <sup>d</sup> 55/76 (72)         15 (63)         40 (75)           Blood culture positive         48/70 (69)         18/23 (78)         30/47 (64)           During hospital stay         20         10 (19)         32 (60)           Any neurological sequelae <sup>b</sup> 46 (60)         14 (58)         32 (60)           Intensive care unit admission         26 (34)         6 (25)         20 (38)           Adjunctive anticonvulsant treatment         14 (18)         7 (29)         7 (13)           Operative treatmen	Cranial nerve palsy <sup>c</sup>	3/70 (4)	0/22 (0)	3/48 (6)
C-reactive protein (mg/L) day1 (n=75)       90 (45–189)       82.5 (33.5–99.25)       97 (53–199)         Blood culture positive (n=69)       47 (61)       18 (75)       29/45 (64)         CSF leucocyte count (x10 <sup>6</sup> /L) day1 (n=70)       1359 (213–2923)       1920 (592–3028)       1130 (125–3200)         CSF protein (mg/L) (n=66)       1706 (985–2753)       1846.5 (1226–2435)       1291(702–3140)         CSF erythrocytes (x10 <sup>6</sup> /L) (n=68)       161 (30–697)       418 (54–3310)       180 (17–660) <sup>0.033</sup> CSF glucose (mmol/L) (n=63)       2.3 (0.9–3.6)       1.85 (1.2–2.5)       2.9 (1.0–4.1)         CSF culture detection of pathogen <sup>d</sup> 55/76 (72)       15 (63)       40 (75)         Blood culture positive       48/70 (69)       18/23 (78)       30/47 (64)         During hospital stay       13 (17)       3 (13)       10 (19)         Seizures       18 (23)       10 (42)       8 (15) <sup>0.025</sup> Any neurological sequelae <sup>b</sup> 46 (60)       14 (58)       32 (60)         Intensive care unit admission       26 (34)       6 (25)       20 (38)         Adjunctive anticonvulsant treatment       14 (18)       7 (29)       7 (13)         Operative treatment       12 (16)       12 (23) <sup>0.01/4</sup> 12 (23) <sup>0.01/4</sup>	B-Leukocytes ( $\times 10^9$ ), day1 ( $n = 75$ )	12.0 (5.9–19.6)	6.7 (3.5–13.3)	$15.1 (8.1-22.3)^{0.003}$
Blood culture positive (n=69)         47 (61)         18 (75)         29/45 (64)           CSF leuccoyte count (× 10 <sup>6</sup> /L) day1 (n=70)         1359 (213-2923)         1920 (592-3028)         1130 (125-3200)           CSF protein (mg/L) (n=66)         1706 (985-2753)         1846.5 (1226-2435)         1291(702-3140)           CSF erythrocytes (× 10 <sup>6</sup> /L) (n=68)         161 (30-697)         418 (54-3310)         180 (17-660) <sup>0.033</sup> CSF glucose (nmol/L) (n=63)         2.3 (0.9-3.6)         1.85 (1.2-2.5)         2.9 (1.0-4.1)           CSF culture detection of pathogen <sup>d</sup> 55/76 (72)         15 (63)         40 (75)           Blood culture positive         45/70 (69)         18/23 (78)         30/47 (64)           During hospital stay         13 (17)         3 (13)         10 (19)           Seizures         18 (23)         10 (42)         8 (15) <sup>0.025</sup> Any neurological sequelae <sup>b</sup> 46 (60)         14 (58)         32 (60)           Intensive care unit admission         26 (34)         6 (25)         20 (38)           Adjunctive anticonvulsant treatment         14 (18)         7 (29)         7 (13)           Operative treatment         12 (23) <sup>0.01/4</sup> 12 (23) <sup>0.01/4</sup> 12 (23) <sup>0.01/4</sup>	C-reactive protein (mg/L) day1 ( $n = 75$ )	90 (45–189)	82.5 (33.5–99.25)	97 (53–199)
CSF leucocyte count (× 10 <sup>6</sup> /L) day1 (n=70)       1359 (213–2923)       1920 (592–3028)       1130 (125–3200)         CSF protein (mg/L) (n=66)       1706 (985–2753)       1846.5 (1226–2435)       1291(702–3140)         CSF erythrocytes (× 10 <sup>6</sup> /L) (n=68)       161 (30–697)       418 (54–3310)       180 (17–660) <sup>0.033</sup> CSF glucose (mmol/L) (n=63)       2.3 (0.9–3.6)       1.85 (1.2–2.5)       2.9 (1.0–4.1)         CSF culture detection of pathogen <sup>d</sup> 55/76 (72)       15 (63)       40 (75)         Blood culture positive       48/70 (69)       18/23 (78)       30/47 (64)         During hospital stay       13 (17)       3 (13)       10 (19)         Seizures       18 (23)       10 (42)       8 (15) <sup>0.025</sup> Any neurological sequelae <sup>b</sup> 46 (60)       14 (58)       32 (60)         Intensive care unit admission       26 (34)       6 (25)       20 (38)         Adjunctive anticonvulsant treatment       14 (18)       7 (29)       7 (13)         Operative treatment       12 (16)       -       12 (23) <sup>0.014</sup> Neuroadiological complication       37/66 (56)       13/23 (57)       24/44 (55)	Blood culture positive $(n=69)$	47 (61)	18 (75)	29/45 (64)
CSF protein (mg/L) (n=66)       1706 (985-2753)       1846.5 (1226-2435)       1291(702-3140)         CSF erythrocytes (x10 <sup>6</sup> /L) (n=68)       161 (30-697)       418 (54-3310)       180 (17-660) <sup>0.033</sup> CSF glucose (mmo/L) (n=63)       2.3 (0.9-3.6)       1.85 (1.2-2.5)       2.9 (1.0-4.1)         CSF culture detection of pathogen <sup>d</sup> 55/76 (72)       15 (63)       40 (75)         Blood culture positive       48/70 (69)       18/23 (78)       30/47 (64)         During hospital stay       55/76       3 (13)       10 (19)         Seizures       18 (23)       10 (42)       8 (15) <sup>0.025</sup> Any neurological sequelae <sup>b</sup> 46 (60)       14 (58)       32 (60)         Intensive care unit admission       26 (34)       6 (25)       20 (38)         Adjunctive anticonvulsant treatment       14 (18)       7 (29)       7 (13)         Operative treatment       12 (16)       -       12 (23) <sup>0.014</sup> Neuroradiological complication       37/66 (56)       13/23 (57)       24/44 (55)	CSF leucocyte count ( $\times 10^6$ /L) day1 ( $n = 70$ )	1359 (213–2923)	1920 (592–3028)	1130 (125–3200)
CSF erythrocytes (× 10 <sup>6</sup> /L) (n=68)         161 (30–697)         418 (54–3310)         180 (17–660) <sup>0.033</sup> CSF glucose (mmol/L) (n=63)         2.3 (0.9–3.6)         1.85 (1.2–2.5)         2.9 (1.0–4.1)           CSF culture detection of pathogen <sup>d</sup> 55/76 (72)         15 (63)         40 (75)           Blood culture positive         48/70 (69)         18/23 (78)         30/47 (64)           During hospital stay         7         3 (13)         10 (19)           Seizures         18 (23)         10 (42)         8 (15) <sup>0.025</sup> Any neurological sequelae <sup>b</sup> 46 (60)         14 (58)         32 (60)           Intensive care unit admission         26 (34)         6 (25)         20 (38)           Adjunctive anticonvulsant treatment         14 (18)         7 (29)         7 (13)           Operative treatment         12 (16)         -         12 (23) <sup>0.014</sup> Neuroradiological complication         37/66 (56)         13/23 (57)         24/44 (55)	CSF protein (mg/L) $(n=66)$	1706 (985–2753)	1846.5 (1226–2435)	1291(702–3140)
CSF glucose (mmol/L) (n=63)       2.3 (0.9–3.6)       1.85 (1.2–2.5)       2.9 (1.0–4.1)         CSF culture detection of pathogen <sup>d</sup> 55/76 (72)       15 (63)       40 (75)         Blood culture positive       48/70 (69)       18/23 (78)       30/47 (64)         During hospital stay       7       3 (13)       10 (19)         Seizures       18 (23)       10 (42)       8 (15) <sup>0.025</sup> Any neurological sequelae <sup>b</sup> 46 (60)       14 (58)       32 (60)         Intensive care unit admission       26 (34)       6 (25)       20 (38)         Adjunctive anticonvulsant treatment       14 (18)       7 (29)       7 (13)         Operative treatment       12 (16)       -       12 (23) <sup>0.014</sup> Neuroradiological complication       37/66 (56)       13/23 (57)       24/44 (55)	CSF erythrocytes ( $\times 10^6$ /L) ( $n = 68$ )	161 (30-697)	418 (54–3310)	180 (17–660) <sup>0.033</sup>
CSF culture detection of pathogen <sup>d</sup> 55/76 (72)       15 (63)       40 (75)         Blood culture positive       48/70 (69)       18/23 (78)       30/47 (64)         During hospital stay       7       7       7         Coma       13 (17)       3 (13)       10 (19)         Seizures       18 (23)       10 (42)       8 (15) <sup>0.025</sup> Any neurological sequelae <sup>b</sup> 46 (60)       14 (58)       32 (60)         Intensive care unit admission       26 (34)       6 (25)       20 (38)         Adjunctive anticonvulsant treatment       14 (18)       7 (29)       7 (13)         Operative treatment       12 (16)       -       12 (23) <sup>0.014</sup> Neuroradiological complication       37/66 (56)       13/23 (57)       24/44 (55)	CSF glucose (mmol/L) $(n=63)$	2.3 (0.9–3.6)	1.85 (1.2–2.5)	2.9 (1.0-4.1)
Blood culture positive         48/70 (69)         18/23 (78)         30/47 (64)           During hospital stay	CSF culture detection of pathogen <sup>d</sup>	55/76 (72)	15 (63)	40 (75)
During hospital stay         I3 (17)         3 (13)         10 (19)           Seizures         18 (23)         10 (42)         8 (15) <sup>0.025</sup> Any neurological sequelae <sup>b</sup> 46 (60)         14 (58)         32 (60)           Intensive care unit admission         26 (34)         6 (25)         20 (38)           Adjunctive anticonvulsant treatment         14 (18)         7 (29)         7 (13)           Operative treatment         12 (16)         -         12 (23) <sup>0.014</sup> Neuroradiological complication         37/66 (56)         13/23 (57)         24/44 (55)	Blood culture positive	48/70 (69)	18/23 (78)	30/47 (64)
Coma         13 (17)         3 (13)         10 (19)           Seizures         18 (23)         10 (42)         8 (15) <sup>0.025</sup> Any neurological sequelae <sup>b</sup> 46 (60)         14 (58)         32 (60)           Intensive care unit admission         26 (34)         6 (25)         20 (38)           Adjunctive anticonvulsant treatment         14 (18)         7 (29)         7 (13)           Operative treatment         12 (16)         -         12 (23) <sup>0.014</sup> Neuroradiological complication         37/66 (56)         13/23 (57)         24/44 (55)	During hospital stay			
Seizures         18 (23)         10 (42)         8 (15) <sup>0.025</sup> Any neurological sequelae <sup>b</sup> 46 (60)         14 (58)         32 (60)           Intensive care unit admission         26 (34)         6 (25)         20 (38)           Adjunctive anticonvulsant treatment         14 (18)         7 (29)         7 (13)           Operative treatment         12 (16)         -         12 (23) <sup>0.014</sup> Neuroradiological complication         37/66 (56)         13/23 (57)         24/44 (55)	Coma	13 (17)	3 (13)	10 (19)
Any neurological sequelae <sup>b</sup> 46 (60)       14 (58)       32 (60)         Intensive care unit admission       26 (34)       6 (25)       20 (38)         Adjunctive anticonvulsant treatment       14 (18)       7 (29)       7 (13)         Operative treatment       12 (16)       -       12 (23) <sup>0.014</sup> Neuroradiological complication       37/66 (56)       13/23 (57)       24/44 (55)	Seizures	18 (23)	10 (42)	8 (15) <sup>0.025</sup>
Intensive care unit admission         26 (34)         6 (25)         20 (38)           Adjunctive anticonvulsant treatment         14 (18)         7 (29)         7 (13)           Operative treatment         12 (16)         -         12 (23) <sup>0.014</sup> Neuroradiological complication         37/66 (56)         13/23 (57)         24/44 (55)	Any neurological sequelae <sup>b</sup>	46 (60)	14 (58)	32 (60)
Adjunctive anticonvulsant treatment       14 (18)       7 (29)       7 (13)         Operative treatment       12 (16)       -       12 (23) <sup>0.014</sup> Neuroradiological complication       37/66 (56)       13/23 (57)       24/44 (55)	Intensive care unit admission	26 (34)	6 (25)	20 (38)
Operative treatment         12 (16)         -         12 (23) <sup>0.014</sup> Neuroradiological complication         37/66 (56)         13/23 (57)         24/44 (55)	Adjunctive anticonvulsant treatment	14 (18)	7 (29)	7 (13)
Neuroradiological complication         37/66 (56)         13/23 (57)         24/44 (55)	Operative treatment	12 (16)	-	12 (23) <sup>0.014</sup>
	Neuroradiological complication	37/66 (56)	13/23 (57)	24/44 (55)

<sup>a</sup>Urinary tract infection in 17, otitis media/acute mastoiditis in 8, sinusitis in 6, pneumonia and arthritis in 2 each, and skin infection, and pleural empyema in one each

<sup>b</sup>Defined as seizures, dizziness, cranial nerve palsy, hemiparesis, aphasia/dysphasia, isolated hypotonia/motor delay, ataxia, any psychomotor retardation, hearing impairment, papillary stasis, hydrocephalus, or memory difficulties

<sup>c</sup>Ptosis, abducens paresis, and strabismus in one

<sup>d</sup>Includes patients diagnosed by CSF with positive CSF culture (n=44), non-culture detection of bacterial DNA or antigen in CSF (n=8), and detection of bacteria on CSF Gram stain (n=1). Two mycobacterium tuberculosis meningitis with positive B-LyTbIFN/Tb-Spot test. One lumbar puncture failed Statistical significance when P < 0.05.

**Table 2**Aetiology of bacterialmeningitis in children inSouthern Finland, 2010–2021

Pathogen	All N=77 (%)	Children aged $< 2$ months old N=24 (%)	Children aged $\geq 2$ months old N=53 (%)
Unknown causative agent	22 (29)	9 (39)	13 (14)
Neisseria meningitidis	12 (16)	-	12 (23) 0.020
Streptococcus pneumonia	12 (16)	1 (4)	11 (21)
Haemophilus influenzae type b	2 (3)	-	2 (4)
Group B streptococcus (GBS)	13 (17)	11 (46)	2 (4) <.0001
Staphylococcus aureus	6 (8)	1 (4)	5 (9)
Escherichia coli	4 (5)	2 (8)	2 (4)
Pseudomonas aeruginosa	1 (1)	-	1 (2)
Staphylococcus epidermis	1 (1)	-	1 (2)
Staphylococcus hominis	1 (1))	-	1 (2)
Gram positive cocci	1(1)	-	1 (2)
Mycobacterium tuberculosis	2 (3)	-	2 (4)

Statistical significance when P < 0.05.

 Table 3
 The hearing results in children with BM

	All children (%)
The number of children tested for hearing	49/77 (64)
Possible fluctuations in hearing levels after BM	5/49 (10)
The final hearing according to BEHL $(N=49)$	
Hearing normal	47/49 (96)
Hearing loss (26–79 dB HL)	-
Deaf	2/49 (4)
The final hearing thresholds, ear-specific $(N=98)$	
Hearing normal	92/98 (94)
Hearing loss (26–79 dB HL) <sup>a</sup>	1/98 (1)
Deaf <sup>b</sup>	5/98 (5)

BM bacterial meningitis, BOA behavioral observation audiometry

dB, decibel, BEHL, better ear hearing level

<sup>a</sup>The grade of hearing loss unclear (hearing tested by BOA)

<sup>b</sup>Streptococcus pneumoniae in four ears, Neisseria meningitidis in one ear

Neuroradiological complication occurred in 37 out of 66 (56%) scanned patients. The most common findings were pus in subdural, subarachnoidal space or in lateral ventricles (n = 15), the presence of newly acquired or acerbation of hydrocephalus (n = 10), haemorrhage (n = 9), unknown subdural effusion/hygroma (n = 7), infarction (n = 6), labyrinthitis (n = 4), and venous infarction and brain herniation in three each. Brain oedema, encephalitis, narrowing of ICA lumen, and spinal epidural abscess were seen in one each. Haemorrhage was diagnosed (30% (7/23)) more often in infants < 2 months old compared with (5% (2/44), P = 0.006) children  $\ge 2$  months old.

Table 3 shows the hearing results. Hearing was tested mainly after hospitalization in 49 out of 77 patients (62%);

only one child was tested during hospital stay (3 days after arrival). The initial hearing test was done at a median of 1.8 months after BM diagnosis (IQR 3 weeks to 2 months). Forty-seven out of 49 (96%) children were diagnosed as having normal hearing, and two children were diagnosed with deafness. Possible fluctuation in hearing levels was seen in 5/49 (10%) children.

#### Outcome

Tables 4 and 5 summarize the clinical outcome. The median duration of hospital stay was 13 days (IQR 8–17 days). At discharge, an unfavourable outcome was observed in 19/70 (27%) BM survivors. Seven (9%) children died within 4 days of admission; 85% (6/7) were boys (age range 1.3 months to 15 years and 11 months at the time of death). Of seven deaths, three were due to meningococcal disease, two *S. pneumoniae*, one *S. aureus*, and one GBS.

At discharge, neurological sequelae occurred in 24 (34%) of 70 survivors, with dizziness as the most common (9/70; 13%). In the follow-up after hospital discharge, long-term neurological sequelae were diagnosed in 19/60 (32%) patients, aphasia/dysphasia being the most common in 10/60 (17%). Hearing loss/deafness was diagnosed in only two (3%) children. The median follow-up was 1 year (IQR 0.3-3.4 years).

Table 4 summarizes the risk factors for death, an unfavourable outcome at discharge, and long-term neurological sequelae. In univariate analysis, a patient diagnosed with petechiae prior to hospital admission (13.2 (1.52–114.52), P=0.019), altered level of consciousness with neurological sequelae on admission (12.27 (1.39–108.30), P=0.024), seizures on admission (8.53 (1.15–63.52), P=0.036), or Table 4Outcome of childrendiagnosed with bacterialmeningitis in Southern Finland,2010 2020

	All N=77 (%)	Children < 2 months old $N=24$ (%)	Children $\geq 2$ months old N=53 (%)
Any neurological sequelae at discharge $(n=70)$	24/70 (34)	7/22 (32)	17/48 (35)
Dizziness	9/70 (13)	-	9/48 (19)
Isolated hypotonia/motor delay	9/70 (13)	4/22 (18)	5/48 (10)
Seizure disorder	5/70 (7)	2/22 (9)	3/48 (6)
Cranial nerve palsy <sup>a</sup>	3/70 (4)	1/22 (5)	2/48 (4)
Hearing loss/deafness <sup>b</sup>	2/70 (3)	-	2/48 (4)
Hemiparesis	2/70 (3)	-	2/48 (4)
Any psychomotor retardation	1/70 (1)	-	1/48 (2)
Ataxia	1/70 (1)	-	1/48 (2)
Aphasia/dysphasia	1/70 (1)	-	1/48 (2)
Glasgow Outcome Score at discharge			
1	7 (9)	2 (8)	5 (9)
2	-	-	-
3	7 (9)	2 (8)	5 (9)
4	5 (6)	1 (4)	4 (8)
5	58 (75)	20 (83)	38 (72)
Long-term sequelae $(n=60)$	19/60 (32)	8/21 (38)	11/39 (28)
Aphasia/dysphasia	10/60 (17)	5/21 (24)	5/39 (13)
Learning difficulties	5/60 (8)	1/21 (5)	4/39 (10)
Isolated hypotonia/motor delay	3/60 (5)	2/21 (10)	1/39 (3)
Hearing loss (deafness $n=2$ ) <sup>b</sup>	2/60 (3)	-	2/39 (5)
Seizure disorder	2/60 (3)	2/21 (10)	-
Dizziness	1/60 (2)	-	

<sup>a</sup>Abducens nerve palsy in two, double vision in one

<sup>b</sup>Includes two patients with cochlea implants, both had pneumococcal aetiology

Statistical significance when P < 0.05.

seizures during hospital stay (5.33 (1.07–26.61), P=0.041) showed higher odds for death. Also, SD effusion on imaging (7.60 (1.02–56.68), P=0.48) showed higher odds for a fatal outcome.

### Discussion

Our article is an overview of childhood BM in Southern Finland and its prognostic factors for poor outcomes in 2010–2020. We evaluated the incidence rate, bacteriology, predisposing factors, clinical characteristics, and outcome. The overall incidence rate of BM remained quite stable, at an average of 2.2/100,000/year in infants and children.

Increased use of vaccination against the predominant pathogens has decreased the global incidence of childhood BM in developed countries [10]. The leading pathogen of BM in our paediatric cohort among children  $\geq 2$  months old was *Neisseria meningitidis*, followed by *Streptococcus pneumoniae*. The 10-valent pneumococcal conjugate vaccine was added to the Finnish national vaccination programme in the autumn of 2010, at the beginning of our period under study. In our study, the major causative organism among infants <2 months of age remained GBS, as previously published [3, 13]. The fatality rate was 9% in our paediatric cohort. All deaths were related to CABM, and our result is in line with what has previously been reported (3-10%) [2–5]. Despite advances in modern medicine, the overall case fatality rate has not significantly decreased in the twenty-first century in the developed world.

In our data, some children experienced neurological symptoms upon discharge from hospital, and some of them were diagnosed with neurological sequelae during followup. Long-term neurological sequelae were common in our series, being present in 32% of BM survivors. The long-term neurological sequelae were slightly more common in infants < 2 months old compared with children  $\geq$  2 months old, 38% vs. 28% respectively. Infants < 2 months old are the most vulnerable age group, with a higher risk for BM sequelae. These results are consistent with previously reported studies and highlight the persistent challenges regarding childhood BM [5, 13, 14].

Table 5	Univariate analysis-	—the risk factors for	GOS1/death,	unfavourable or	utcome, and	long-term neuro	ological	sequelae
---------	----------------------	-----------------------	-------------	-----------------	-------------	-----------------	----------	----------

	GOS1/death (n=7)		Unfavourable outcome $(n=19)$		Long-term neurological sequelae $(n=19)$	
	OR (95%, CI)	P-value	OR (95%, CI)	P-value	OR (95%, CI)	P-value
Demographics, prior hospital admission						
Age $\geq 2$ months	1.15 (0.20-6.37)	0.88	1.97 (0.58-6.74)	0.28	0.80 (0.25-2.49)	0.70
Male	5.05 (0.58-44.19)	0.14	2.61 (0.83-8.20)	0.10	1.48 (0.49–4.52)	0.49
Otitis media/acute mastoiditis or sinusitis	0.0 (0.00–)	1.0	1.14 (0.32-4.11)	0.84	0.51 (0.12-2.10)	0.35
Petechia prior hospital	13.2 (1.52–114.52)	0.019	3.18 (0.42-24.29)	0.27	2.17 (0.13-36.62)	0.59
Altered level of consciousness prior hospital	11.62 (2.15-62.9)	0.004	1.87 (0.48-7.26)	0.37	0.0 (0.0–)	1.0
During hospital admission						
Dyspnoea at admission	24.43 (2.23–268.06)	0.009	2.85 (0.69–11.85)	0.15	0.0 (0.0–)	1.0
Seizures at admission	8.53 (1.15-63.52)	0.036	15.71 (1.63–151.88)	0.017	1-12 (0.10-13.18)	0.93
Any neurological sequelae at admission	7.97 (1.41-45.10)	0.019	5.11 (1.64–15.98)	0.005	0.47 (0.11-1.92)	0.29
Any neurological sequelae at admis- sion + altered level of consciousness at admis- sion	12.27 (1.39–108.30)	0.024	2.64 (0.89–7.82)	0.08	0.27 (0.07–1.09)	0.07
Coma at admission	11.81 (1.94–71.90)	0.007	1.63 (0.27–9.71)	0.59	0.0 (0.0–)	1.0
Pneumococcal aetiology	1.6 (0.27–9.49)	0.61	1.76 (0.47-6.56)	0.40	0.92 (0.19-4.34)	0.91
CSF leucocyte count < $100 (\times 10^6/L)$	13.5 (1.29 –151.28)	0.03	1.18 (0.32–5.32)	0.81	1.89 (0.44-8.09)	0.39
During hospital stay						
Coma during hospital stay	54.00 (5.66-515.64)	< 0.001	3.36 (0.96–11.72)	0.057	3.38 (0.67–16.93)	0.14
Normal level of consciousness during hospital stay	0.49 (0.006–0.44)	0.007	0.44 (0.15–1.30)	0.14	1.06 (0.28–3.98)	0.94
Seizures during hospital stay	5.33 (1.07-26.61)	0.041	4.90 (1.56–15.43)	0.007	1.14 (0.63–7.93)	0.21
Any neurological sequelae during hospital stay	1.77 (0.32–9.75)	0.51	8.50 (1.80-40.17)	0.007	1.67 (0.81-8.77)	0.11
Petechia during hospital stay	6.75 (1.25–36.52)	0.027	0.71 (0.14–3.81)	0.71	1.09 (0.18-6.53)	0.93
Neuroradiological complication	$25 \times 10^8 (0.0-)$	1.0	9.55 (1.97-46.23)	0.005	1.60 (0.50–5.13)	0.43
Infarction	2.85 (0.66-30.62)	0.39	7.39 (1.22–44.88)	0.030	0.50 (0.05-4.85)	0.55
Newly acquired or acerbation of hydrocephalus	$13 \times 10^8 (0.0-)$	1.0	4.80 (1.23–18.67)	0.024	1.47 (0.22–9.71)	0.69
SD effusion NAS	7.60 (1.02–56.68)	0.048	2.46 (0.49-12.35)	0.27	0.0 (0.0–)	1.0
Adjunctive anticonvulsant treatment	1.93 (0.34–11.17)	0.46	6.30 (1.82–21.83)	0.004	0.77 (0.18-3.31)	0.73
Operative treatment	0 (0–)	1.0	5.06 (1.44–17.79)	0.012	2.57 (0.64–10.27)	0.18
Intensive care unit admission	15.0 (1.70–132.64)	0.015	2.92 (1.002-8.49	0.050	1.11 (0.34–3.62)	0.86

Statistical significance when P < 0.05.

In our study, the most common long-term neurological sequelae were aphasia/dysphasia, followed by learning difficulties and isolated hypotonia/motor delay. Svendsen et al. found that abnormalities on cranial imaging, pneumococcal aetiology, and seizures during admission were more often related to the long-term neurological sequelae. However, we found no independent risk factors in logistic regression univariate analysis in relation to long-term neurological sequelae. In our cohort, the neuroradiological complications seem to predict an unfavourable outcome in BM at discharge. However, over the long term, a statistically significant association was no longer observed. Pneumococcal aetiology as an independent factor has also previously been associated with increased risk for long-term neurological sequelae [1, 5, 6, 8]. In our study, however, no statistically significant association was found. This might be partly due to the limited sample size in our data.

The prevalence of post-meningitis hearing loss is known [5, 6, 9, 15]. In our cohort, 64% of children underwent hearing assessments, which is less than ideal. This issue needs to be given more attention in the future. Future guidelines must be revised to ensure that hearing is assessed in every individual diagnosed with BM [16]. The incidence of hearing loss (3%) in our study was lower compared with previous reports, where it has been the most common neurological sequela (14–35%) [4–6]. Both children with hearing loss became deaf; less severe hearing loss was not detected. In earlier studies, bilateral severe to profound hearing loss has been reported in approximately 1–5% of BM survivors, and this is in line with 3% in our study [9, 17]. We observed possible transient fluctuation in hearing levels after BM in 10%. In the prospective BM study by Dodge et al., transient hearing loss was found in 16% of children [18].

It is imperative to monitor hearing during BM because associated bacterial labyrinthitis may lead to partial or total ossification of the labyrinth [19], as was the case in the two patients in our study with profound hearing loss. In this case, insertion of the cochlear implant electrode may become very challenging. If cochlear implantation seems necessary, imaging should be performed. The best results with cochlear implants for a deaf ear are obtained when the procedure is performed without significant delay [20]. Hearing loss is usually associated with *Str. pneumonia* [4, 5, 8, 9], as we also found in both patients with profound hearing loss. Karppinen et al. found that *S. pneumoniae* was the most common cause of impaired hearing at a > 60 dB threshold among children with BM, and it caused deafness more often than Hib and *N. meningitidis* [21].

The treatment protocols of BM, early diagnosis, prompt administration of appropriate antimicrobial agents, and comprehensive supportive care may have together contributed to a more favourable outcome in terms of neurological sequelae due to BM. This finding underscores the importance of not only identifying the causative agents of BM but also implementing effective therapeutic strategies to prevent the immediate and long-term consequences of BM. Quick access to treatment is crucial when treating childhood BM. The availability of intensive care, close monitoring, and efficient management of patients when they are having seizures is very important. This also supports spontaneous recovery tendency in childhood BM.

The main limitation in our study was its retrospective nature, but the treatment protocol for BM is considerably standardized in our tertiary centre. Another limitation is our small sample size due to our country's small population and the low incidence of BM. In addition, 14% of survivors of BM were lost to follow-up. Despite the imaging and auditory monitoring of patients not being entirely comprehensive, we obtained valuable information regarding the aetiology and long-term sequelae of childhood BM.

One of the best ways to prevent BM is to have effective coverage of conjugate vaccines against the main causes of BM. Infants aged < 2 months are the most vulnerable age group, having the greatest risk for long-term BM sequelae. In future, an effective maternal vaccine for GBS is needed for this vulnerable age group [22, 23].

This study highlights the high fatality risk in childhood BM. Furthermore, long-term neurological sequelae persist among BM survivors, with aphasia/dysphasia being the most common. The incidence of profound hearing loss was 3%. Despite the high morbidity of BM, children tend to have a good recovery.

Acknowledgements This study was funded by The Research Foundation of Helsinki University Hospital (HUS Medical Imaging Center and Head and Neck Center), Finnish Society for Study of Infectious Diseases and The Finnish ORL-HNS Foundation. This study got the grant for an English language editing service and financial support from Pediatric Research Center. Thank you, ophthalmologist Risto Hyväkkö, for your help.

Authors' Contributions L Lempinen and J Jero contributed to the research conception and design. T Nieminen had also a major role setting up the retrospective BM research. L Lempinen collected and analysed the research data and drafted the initial manuscript. T Nieminen and J Jero were major contributors in interpreting the data. R Saat and L Lempinen reviewed the radiological imaging findings. A Aarnisalo and L Lempinen analysed the hearing findings. All authors reviewed and approved the final manuscript.

**Funding** Open Access funding provided by University of Helsinki (including Helsinki University Central Hospital). This study was funded by The Research Foundation of Helsinki University Hospital (HUS Medical Imaging Center and Head and Neck Center), the Finnish Society for Study of Infectious Diseases, and the Finnish ORL-HNS Foundation. This study got the grant for an English language editing service and financial support from the Pediatric Research Center, Helsinki University Hospital.

**Data availability** Study data can be provided upon reasonable request by the corresponding author.

#### Declarations

**Ethics approval** The study protocol was approved by the Helsinki University Central Hospital Pediatric Research Center. Approval from the local Ethics Committee was not required for a retrospective type of study in the Helsinki University Hospital region when the study was conducted.

Competing interests The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

### References

- Zunt JR, Kassebaum NJ, Blake N et al (2018) Global, regional, and national burden of meningitis, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17(12):1061–1082. https://doi.org/10.1016/S1474-4422(18) 30387-9
- Nigrovic LE, Kuppermann N, Malley R (2008) Children with bacterial meningitis presenting to the emergency department during the pneumococcal conjugate vaccine era. Acad Emerg Med 15(6):522–528. https://doi.org/10.1111/j.1553-2712.2008.00117.x

- Thigpen MC, Whitney CG, Messonnier NE et al (2011) Bacterial meningitis in the United States, 1998–2007. N Engl J Med 364(21):2016–2025. https://doi.org/10.1056/NEJMoa1005384
- Chavez-Bueno S, McCracken Jr GH. Bacterial meningitis in children. *Pediatr Clin North Am*. 2005;52(3):795–810, vii. S0031–3955(05)00038–6 [pii]
- Svendsen MB, Ring Kofoed I, Nielsen H, Schønheyder HC, Bodilsen J (2020) Neurological sequelae remain frequent after bacterial meningitis in children. Acta Paediatr 109(2):361–367. https:// doi.org/10.1111/apa.14942
- Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I (2010) Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. The LancetInfectious diseases 10(5):317–328. https://doi.org/10. 1016/S1473-3099(10)70048-7[doi]
- Chandran A, Herbert H, Misurski D, Santosham M (2011) Longterm sequelae of childhood bacterial meningitis. Pediatric Infectious Disease Journal 30(1):3–6. https://doi.org/10.1097/INF. 0b013e3181ef25f7
- Baraff LJ, Lee SI, Schriger DL (1993) Outcomes of bacterial meningitis in children: a meta-analysis. Pediatr Infect Dis J 12(5):389–394
- Wellman MB, Sommer DD, McKenna J (2003) Sensorineural hearing loss in postmeningitic children. Otol Neurotol 24(6):907–912
- McIntyre PB, O'Brien KL, Greenwood B, van de Beek D (2012) Effect of vaccines on bacterial meningitis worldwide. The Lancet 380(9854):1703–1711. https://doi.org/10.1016/S0140-6736(12) 61187-8
- Inweregbu K, Dave J, Pittard A (2005) Nosocomial infections. Continuing Education in Anaesthesia Critical Care & Pain 5(1):14–17. https://doi.org/10.1093/bjaceaccp/mki006
- Jennett B, Teasdale G, Braakman R, Minderhoud J, Knill-Jones R (1976) Predicting outcome in individual patients after severe head injury. The Lancet 307(7968):1031–1034. https://doi.org/10. 1016/S0140-6736(76)92215-7
- Okike IO, Johnson AP, Henderson KL et al (2014) Incidence, etiology, and outcome of bacterial meningitis in infants aged <90 days in the United Kingdom and Republic of Ireland: prospective, enhanced, national population-based surveillance. Clin Infect Dis 59(10):e150–e157. https://doi.org/10.1093/cid/ciu514
- Baud O, Aujard Y. Neonatal bacterial meningitis. In: ; 2013:1109– 1113. https://doi.org/10.1016/B978-0-444-52910-7.00030-1

- Persson F, Bjar N, Hermansson A, Gisselsson-Solen M (2022) Hearing loss after bacterial meningitis, a retrospective study. Acta Otolaryngol 142(3–4):298–301. https://doi.org/10.1080/00016 489.2022.2058708
- Jensen ES, Cayé-Thomasen P, Bodilsen J, et al. Hearing loss in bacterial meningitis revisited—evolution and recovery. *Open Forum Infect Dis.* 2023;10(3). https://doi.org/10.1093/ofid/ofad056
- Fortnum HM (1992) Hearing impairment after bacterial meningitis: a review. Arch Dis Child 67(9):1128–1133. https://doi.org/ 10.1136/adc.67.9.1128
- Dodge PR, Davis H, Feigin RD et al (1984) Prospective evaluation of hearing impairment as a sequela of acute bacterial meningitis. N Engl J Med 311(14):869–874. https://doi.org/10.1056/NEJM1 98410043111401[doi]
- Tinling SP, Colton J, Brodie HA (2004) Location and timing of initial osteoid deposition in postmeningitic labyrinthitis ossificans determined by multiple fluorescent labels. Laryngoscope 114(4):675–680. https://doi.org/10.1097/00005537-20040 4000-00015
- Douglas SA, Sanli H, Gibson WP (2008) Meningitis resulting in hearing loss and labyrinthitis ossificans - does the causative organism matter? Cochlear Implants Int 9(2):90–96. https://doi. org/10.1179/cim.2008.9.2.90[doi]
- Karppinen M, Pelkonen T, Roine I, Cruzeiro ML, Peltola H, Pitkaranta A (2015) Hearing impairment after childhood bacterial meningitis dependent on etiology in Luanda. Angola Int J Pediatr Otorhinolaryngol 79(11):1820–1826. https://doi.org/10.1016/j. ijporl.2015.08.015[doi]
- Absalon J, Simon R, Radley D, et al. Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches. *Hum Vaccin Immunother*. 2022;18(1). https://doi.org/10.1080/ 21645515.2022.2037350
- Delara M, Vadlamudi NK, Sadarangani M (2023) Strategies to prevent early and late-onset group B streptococcal infection via interventions in pregnancy. Pathogens 12(2):229. https://doi.org/ 10.3390/pathogens12020229

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.